| 名称 | PDL2/TCR Activator/CHO |
| 型号 | CBP74065 |
| 报价 |  |
| 特点 | PDL2/TCR Activator/CHO，冻存条件：90% FBS+10% DMSO； |
产品搜索
相关文章
联系我们
联系人：蒋经理
电话：4008750250
号码：
手机：18066071954
地址：南京市栖霞区纬地路9号
Email： zhangxiangwen@cobioer.com
电话：4008750250
号码：
手机：18066071954
地址：南京市栖霞区纬地路9号
Email： zhangxiangwen@cobioer.com
产品展示 / PRODUCTS
- 详细内容
PDL2/TCR Activator/CHO
| CBP74065 | |
| I. Background | |
| The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes. | |
| II. Description | |
| Recombinant CHO-K1 cells constitutively expressing human PD-L2 (Programmed Cell Death 1 Ligand 2 or CD273, GenBank accession #NM_025239) and an engineered T-cell receptor (TCR) activator. | |
| III. Introduction | |
| Host Cell: | CHO-K1 |
| Expressed gene: | PDL2 |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | Programmed Cell Death 2 Ligand 2, PDL2, PD-L2, CD273, PDCDL1G2, B7-DC |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | F12K+10%FBS+2ug/ml puromycin+500ug/ml hygromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Cricetulus griseus, hamster, Chinese |
| Tissue: | Ovary |
| Disease: | Hamster Chinese ovary |
| Morphology: | Epitheloid cell |
| Growth Properties: | Adherent |
| Ⅴ. Representative Data | |
Figure 1.Recombinant CHO-K1 cells constitutively expressing human PD-L2 (Programmed Cell Death 1 Ligand 2 or CD273, GenBank accession #NM_025239) and an engineered T-cell receptor (TCR) activator. | |
 | |
Figure 2. Dose responese curve of anti-PD-1 neutralizing antibody in PD-1/NFAT-Reporter/Jurkat cells with PD-L2/TCR activator/CHO.The bioassay consists of two genetically engineered cell lines, Jurkat/PD-1/NFAT-Luc Cells and CHO/TCR activator/PD-L2 Cells. When co-cultured, the PD-1/PD-L2 interaction inhibits TCR-mediated luminescence. When the PD-1/PD-L2 interaction is disrupted, TCR activation induced luminescence (via activation of NFAT pathway) that can be detected and quantified using Bio-Glo Reagents | |
